Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

Paediatric Liver Disease, Cholestasis, and Acute Liver Failure: Diagnostic Pathways and Emergency Protocols

Neonatal cholestasis and acute hepatic dysfunction represent high-stakes clinical scenarios in paediatric practice. While physiological jaundice is exceptionally common in healthy newborns, jaundice persisting beyond the immediate neonatal period demands prompt, structured evaluation to identify surgical emergencies such as biliary atresia or rapidly progressive inborn errors of metabolism. Similarly, Paediatric Acute Liver Failure (PALF) carries high mortality and necessitates rapid identification of etiology, neuroprotective critical care, and timely referral for orthotopic liver transplantation. This section explores the physiological principles, diagnostic algorithms, and evidence-based interventions required for the European Board of Paediatrics (EBP-EAP) examination.

---

Prolonged Neonatal Jaundice: Definitions and Diagnostic Stratification

Jaundice is visible when serum bilirubin exceeds 85 micromol/L (5 mg/dL). In the vast majority of term infants, physiological unconjugated jaundice peaks at days 3 to 5 and resolves by day 10 to 14.

Clinical Definitions

• Prolonged Jaundice: Jaundice that persists beyond 14 days of life in full-term infants, or beyond 21 days of life in preterm infants (<37 weeks gestation).
• Mandatory First Investigation: Every infant with prolonged jaundice requires an immediate blood test to measure total serum bilirubin and fractionated (conjugated / direct) bilirubin.

Unconjugated vs Conjugated Hyperbilirubinemia

                             [Prolonged Jaundice (>14d Term / >21d Preterm)]
                                                    |
                                     [Measure Fractionated Bilirubin]
                                                    |
         +------------------------------------------+------------------------------------------+
         |                                                                                     |
  [Unconjugated Hyperbilirubinemia]                                                     [Conjugated Hyperbilirubinemia]
  (Direct bilirubin within laboratory reference range)                                                    (Direct bilirubin >1.0 mg/dL, approximately 17 µmol/L)
         |                                                                                     |
  - Breast milk jaundice (benign, common)                                              - ALWAYS PATHOLOGICAL
  - Congenital hypothyroidism (TSH)                                                    - Pale/acholic stools, dark amber urine
  - Hemolytic disease (G6PD, Spherocytosis)                                            - EMERGENCY HEPATOBILIARY WORKUP
  - Extravasated blood / Cephalhematoma                                                - Exclude biliary atresia urgently; enable early Kasai surgery
  - Crigler-Najjar / Gilbert syndrome

1. Predominantly Unconjugated Hyperbilirubinemia (Direct Bilirubin Within the Laboratory Reference Range):

   • Breast Milk Jaundice: The most frequent cause; occurs in up to 20% to 30% of healthy, thriving breastfed infants. Believed to result from factors in human milk (such as beta-glucuronidase and non-esterified fatty acids) that deconjugate intestinal bilirubin and augment enterohepatic circulation. Infant is healthy, gaining weight appropriately, with normal pale yellow/mustard-colored stools. Jaundice may persist for up to 8 to 12 weeks without adverse sequelae; breastfeeding should NOT be stopped.
   • Congenital Hypothyroidism: Unconjugated hyperbilirubinemia secondary to delayed maturation of hepatic glucuronosyltransferase (UGT1A1); detected on newborn dried blood spot screening (elevated TSH).
   • Hemolysis: Isoimmunization (ABO/Rh), hereditary spherocytosis, Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
   • Inherited Glucuronidation Defects: Gilbert syndrome (mild mutation in UGT1A1 promoter); Crigler-Najjar syndrome types I and II (severe mutations causing profound life-threatening unconjugated hyperbilirubinemia requiring phototherapy or liver transplantation).

2. Conjugated (Cholestatic) Hyperbilirubinemia:

   • Laboratory Definition (ESPGHAN/NASPGHAN): Serum direct bilirubin $>1.0\text{ mg/dL}$ (approximately $17\text{ micromol/L}$) warrants cholestasis evaluation, regardless of the total bilirubin level; a fraction above 20% is not required.
   • Clinical Axiom: Conjugated hyperbilirubinemia is ALWAYS pathological and represents a direct marker of impaired bile formation or biliary flow (cholestasis).
   • Clinical Red Flags:
     • Pale, Clay-Colored, or Acholic Stools: Reduced bile pigment reaching the intestine signals cholestasis and requires urgent evaluation.
     • Dark, Amber Tea-Colored Urine: Water-soluble conjugated bilirubin is excreted in urine, staining diapers.
     • Hepatomegaly: Firm or hard liver edge.
     • Bleeding Diathesis: Bruising, petechiae, or intracranial bleeding caused by impaired absorption of fat-soluble Vitamin K resulting in coagulopathy (elevated PT/INR).
     • Splenomegaly: Suggestive of portal hypertension or storage disease.
     • Faltering Growth: Malabsorption of long-chain triglycerides and fat-soluble vitamins (A, D, E, K).

---

Extrahepatic Biliary Atresia (EHBA)

Biliary atresia is an idiopathic, progressive, inflammatory and fibrosing obliteration of the extrahepatic biliary tree, affecting approximately 1 in 10,000 to 18,000 live births. It is the single most common indication for liver transplantation in childhood, accounting for approximately 50% of all paediatric liver transplants.

Clinical Presentation

• Typically a term infant with normal birth weight who initially appears completely healthy.
• Physiological jaundice fails to clear, or jaundice recurs between 2 and 6 weeks of age.
• The infant develops progressive stool acholia (pale, putty-colored, or white stools) and dark urine.
• The liver becomes progressively enlarged, hard, and non-tender.

Diagnostic Evaluation

• Stool Color Card Evaluation: Validated public health screening tool comparing the infant's stool against standard chromatic photographs.
• High-Resolution Abdominal Ultrasonography: Performed after a 4-hour fast:
  • Triangular Cord Sign: Visualized as a triangular or tubular echogenic density anterior to the bifurcation of the right portal vein ($>4\text{ mm}$ thickness in the transverse plane), representing the fibrous remnant of the porta hepatis. Highly specific (>95%) for biliary atresia.
  • Abnormal Gallbladder Morphology: Gallbladder is absent, diminutive ($<1.5\text{ cm}$ in length), irregular, or fails to contract following a feed ("gallbladder ghost triad").
  • Absence of Extrahepatic Duct Dilatation: The common bile duct is completely absent or non-visualized.
• Hepatobiliary Scintigraphy (HIDA Scan): A selective test of biliary patency. Tracer reaching the intestine supports duct patency, but absent excretion also occurs with severe intrahepatic cholestasis and does not establish biliary atresia. A scan or multi-day phenobarbital priming must not delay timely definitive investigation or surgery.
• Percutaneous Liver Biopsy: Demonstrates ductular proliferation, bile plugs in small interlobular bile ducts, portal tract expansion with edema and fibrosis, and preserved basic lobular architecture.
• Intraoperative Cholangiogram (IOC): The definitive diagnostic gold standard, performed via laparoscopy or mini-laparotomy. Demonstrates complete absence or non-patency of the extrahepatic biliary tree.

                     [Suspected Biliary Atresia]
                                 |
       [Cholestasis: direct >1.0 mg/dL, approximately 17 µmol/L]
              [Pale stools/dark urine increase concern]
                                 |
                 [Urgent specialist assessment]
                                 |
          [Fasting high-resolution abdominal ultrasound]
                                 |
       [Triangular cord/abnormal gallbladder support suspicion]
       [Normal ultrasound DOES NOT exclude biliary atresia]
                                 |
       [Expert-directed biopsy and/or operative cholangiography]
             [Other cholestasis investigations in parallel]
                                 |
               [Cholangiography confirms biliary atresia]
                                 |
             [Prompt KASAI HEPATOPORTOENTEROSTOMY]

Surgical Management: Kasai Hepatoportoenterostomy

• Surgical Procedure: Complete surgical excision of the fibrous extrahepatic biliary ductal remnant up to the porta hepatis, followed by the creation of an end-to-side Roux-en-Y jejunal loop anastomosed directly to the exposed transected microscopic ductules at the porta hepatis to re-establish bile drainage into the gut.
• Critical Timing: Arrange Kasai surgery as soon as possible after confirmation, ideally before 30–45 days of life. Earlier treatment improves bile drainage and native-liver survival, but fibrosis, anatomy and postoperative complications also affect outcome. Do not treat 60 or 90 days as absolute success/failure cutoffs: older infants need urgent specialist assessment for Kasai or transplantation according to their clinical condition.
• Postoperative Complications and Prognosis:
  • Recurrent Ascending Cholangitis: Major postoperative complication (fever, jaundice, acholic stools); prevented with long-term oral antibiotic prophylaxis (co-trimoxazole or neomycin) and treated with high-dose IV broad-spectrum antibiotics.
  • Long-Term Outcome: Even with successful initial bile drainage, progressive intrahepatic fibro-obliteration and portal hypertension occur in many children; approximately 70% to 80% of patients with biliary atresia ultimately require liver transplantation before adulthood.

---

Genetic and Metabolic Etiologies of Paediatric Cholestasis

Clinical Deep Dives

• Alpha-1-Antitrypsin Deficiency: The mutant Z protein (substitution of lysine for glutamate at position 342) misfolds and polymerizes within the rough endoplasmic reticulum of hepatocytes, failing to be secreted. Accumulation of toxic polymers triggers hepatocyte apoptosis and neonatal cholestasis. The pathognomonic histological finding is round, intracytoplasmic globules that stain bright pink with Periodic Acid-Schiff (PAS) and resist digestion by diastase.
• Alagille Syndrome: Clinical diagnostic criteria require liver biopsy demonstration of bile duct paucity plus at least 3 of 5 major clinical criteria:
  1. Hepatic: Chronic cholestasis with intense pruritus and xanthomas.
  2. Cardiac: Congenital cardiovascular defects, most commonly branch / peripheral pulmonary artery stenosis (or Tetralogy of Fallot).
  3. Skeletal: Structural vertebral anomalies, classically butterfly vertebrae (sagittal cleft vertebrae resulting from failure of lateral halves of the vertebral body to fuse) visible on spine radiographs.
  4. Ophthalmologic: Posterior embryotoxon (prominent, anteriorly displaced Schwalbe's line at the junction of the cornea and iris) visible on slit-lamp biomicroscopy.
  5. Facial Features: Characteristic "triangular face" with a broad prominent forehead, deep-set widely spaced eyes (hypertelorism), straight nose, and small pointed chin.

---

Paediatric Acute Liver Failure (PALF)

Paediatric Acute Liver Failure is a rare, devastating clinical syndrome characterized by sudden, catastrophic loss of hepatic metabolic and synthetic capacity in a child with no prior evidence of chronic liver disease.

Diagnostic Criteria (Paediatric Acute Liver Failure Study Group - PALFSG)

Unlike adult criteria, hepatic encephalopathy is not mandatory for diagnosing PALF in young children because encephalopathy is notoriously difficult to detect clinically in infants and toddlers. The established diagnostic triad comprises:

1. Biochemical evidence of acute liver injury (acute elevation of serum aminotransferases ALT/AST) presenting within 8 weeks of symptom onset.
2. No known history of pre-existing chronic liver disease.
3. Severe coagulopathy unresponsive to parenteral Vitamin K administration:
   • Prothrombin Time (PT) $\ge 15\text{ seconds}$ or INR $\ge 1.5$ in the presence of clinical hepatic encephalopathy, OR
   • PT $\ge 20\text{ seconds}$ or INR $\ge 2.0$ in the absence of hepatic encephalopathy.

Age-Specific Etiologies of PALF

• Neonates and Infants (<1 year):
  • Gestational Alloimmune Liver Disease (GALD / Neonatal Hemochromatosis): Maternal IgG antibodies target fetal hepatocytes, driving complement-mediated destruction and severe liver failure at or within hours of birth, accompanied by massive extrahepatic siderosis (sparing the reticuloendothelial system). Treated emergently with maternal IVIG in subsequent pregnancies, and neonatal double-volume exchange transfusion combined with high-dose IVIG (1 g/kg).
  • Infectious: Herpes Simplex Virus (HSV-1, HSV-2) (must initiate immediate IV acyclovir 60 mg/kg/day), enteroviruses (Coxsackie B, echovirus), CMV.
  • Metabolic: Galactosemia (reducing substances in urine; eliminate lactose), Hereditary Tyrosinemia Type 1 (elevated succinylacetone; treated with Nitisinone / NTBC and dietary restriction of tyrosine/phenylalanine), Mitochondrial hepatopathies (POLG mutations; severe lactic acidosis).
• Children and Adolescents (>1 year):
  • Toxin / Drug-Induced: Paracetamol (Acetaminophen) Overdose (accidental or intentional; treated with intravenous N-acetylcysteine [NAC]).
  • Viral Hepatitis: Hepatitis A, hepatitis B and Epstein-Barr virus. Indeterminate PALF: No specific cause is identified despite investigation; this category does not establish viral causation.
  • Autoimmune Hepatitis (AIH Type 1 and Type 2): Elevated IgG, high anti-nuclear (ANA), anti-smooth muscle (SMA), or anti-liver-kidney microsomal (anti-LKM1) antibodies.
  • Wilson Disease: Autosomal recessive copper transport defect (ATP7B mutation).

Wilson Disease Presenting as Acute Liver Failure

Wilson disease can present fulminantly in older children and adolescents, characterized by a unique laboratory fingerprint:

• Coombs-negative intravascular hemolytic anemia (acute release of massive free copper stores lyses erythrocyte membranes).
• Profound jaundice with marked hyperbilirubinemia, but disproportionately modest elevation of alkaline phosphatase. A low ALP-to-total-bilirubin ratio supports suspicion, but depends on the units and is not diagnostic by itself, particularly in children.
• Modest aminotransferase elevation (ALT and AST typically $<1,000\text{ U/L}$ despite fulminant liver failure).
• Low serum ceruloplasmin ($<0.20\text{ g/L}$), markedly elevated 24-hour urinary copper excretion, and presence of Kayser-Fleischer (KF) rings on slit-lamp examination.

---

Critical Care Stabilization and Liver Transplant Referral

                         [Paediatric Acute Liver Failure (PALF)]
                                           |
               [INR ≥ 1.5 with Encephalopathy  OR  INR ≥ 2.0 without]
                                           |
         +---------------------------------+---------------------------------+
         |                                                                   |
  [Immediate Transplant Center Transfer]                              [Critical Care Stabilization]
  - Activate liver transplant team                                    - 10% Dextrose (target glucose 5–7 mmol/L)
  - Avoid delay; high mortality                                       - Head of bed 30°; treat intracranial hypertension if present
                                                                      - AVOID prophylactic FFP (obscures INR tracking)
                                                                      - IV NAC for confirmed/strongly suspected paracetamol toxicity

1. Emergency Transplant Referral: Any child meeting criteria for PALF must be immediately discussed with and transferred to a specialized paediatric liver transplant center. Clinical trajectory can deteriorate precipitously within hours.
2. Metabolic and Glycemic Surveillance: Impaired hepatic gluconeogenesis and glycogenolysis cause severe, refractory hypoglycemia. Continuous intravenous infusion of 10% Dextrose (maintaining blood glucose 5.0 to 7.0 mmol/L) with frequent bedside glucose checks is mandatory.
3. Neuroprotective Protocol (Cerebral Edema Prevention): Hyperammonemia ($>100\text{--}150\text{ micromol/L}$) leads to astrocyte swelling (osmotic accumulation of glutamine), cytotoxic cerebral edema, intracranial hypertension, and brainstem herniation.
   • Elevate head of the bed to 30 degrees in the midline position to optimize cerebral venous drainage.
   • For suspected or confirmed intracranial hypertension, specialists may use hypertonic saline with close sodium/osmolality monitoring; avoid sustained hypernatraemia. This is not routine prophylaxis for every child with PALF.
   • Avoid hypercarbia (maintain $PaCO_2$ between 35 and 40 mmHg if mechanically ventilated).
   • Administer lactulose orally or via nasogastric tube to promote enteric ammonia trapping and excretion.
4. Coagulopathy Management Rules:
   • Administer a single dose of intravenous Vitamin K1 (0.2 mg/kg, max 10 mg) to rule out nutritional deficiency.
   • Avoid blood products solely to normalise INR: they obscure trends and may cause fluid overload. Active bleeding or an invasive procedure may require individually selected plasma, platelets or fibrinogen replacement with specialist input. Recombinant factor VII is exceptional because of thrombosis risk. Transplant assessment uses the evolving clinical picture, including INR and encephalopathy; King's College criteria alone are insufficient for paediatric listing decisions.